Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides

Scientific Reports

Volumn 5, Issue , 2015, Pages

  De Tejada, Guillermo Martinez ^a   Heinbockel, Lena ^b   Ferrer Espada, Raquel ^a   Heine, Holger ^b   Alexander, Christian ^b   Bárcena Varela, Sergio ^a   Goldmann, Torsten ^b   Correa, Wilmar ^b   Wiesmüller, Karl Heinz ^c   Gisch, Nicolas ^b   Sánchez Gómez, Susana ^a   Fukuoka, Satoshi ^d   Schürholz, Tobias ^e   Gutsmann, Thomas ^b   Brandenburg, Klaus ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b RESEARCH CENTER BORSTEL   (Germany)

^c EMC MICROCOLLECTIONS GMBH   (Germany)

^d AIST Shikoku   (Japan)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE; LIPOPROTEIN; LIPOTEICHOIC ACID; PEPTIDE; PEPTIDOGLYCAN; TEICHOIC ACID;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; ENDOTOXEMIA; FEMALE; GRAM NEGATIVE BACTERIUM; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; MONONUCLEAR CELL; MORTALITY; MOUSE; SEPSIS; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; ENDOTOXINS; FEMALE; GRAM-NEGATIVE BACTERIA; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LIPOPROTEINS; MACROPHAGES; MICE; PEPTIDES; PEPTIDOGLYCAN; SEPSIS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS;

EID: 84942163314     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14292     Document Type: Article

References (48)

1. Seam, N. & Suffredini A. F. Mechanisms of sepsis and insights from clinical trials. Drug Disc Today Dis Mech 4, 83-89 (2007).
2. Dellinger, R. P. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic]. Crit Care Med 41, 580-637 (2012).
3. van Zanten, A. R. Unravelling post-ICU mortality: predictors and causes of death. Eur J Anaesthesiol 27, 486-490 (2010).
4. Russell, J. A. Management of sepsis. N Engl J Med 355, 1699-1713 (2006).
5. Hall, M. J., Williams, S. N., DeFrances, C. J. & Golosinskiy, A. Impatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief. 62, 1-8 (2011).
6. Wood, K. A. & Angus, D. C. Pharmacoeconomic implications of new therapies in sepsis. Pharmaco Economics 22, 895-906 (2004).
7. Alexander, C. & Rietschel, E. T. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7, 167-202 (2001).
8. Asanuma, M. et al. Structural evidence of α-aminoacylated lipoproteins of Staphylococcus aureus. FEBS J 278, 716-728 (2011).
9. Nakayama, H., Kurokawa, K. & Lee, B. Lipoproteins in bacteria: structures and biosynthetic pathways. FEBS J 23, 4247-4268 (2012).
10. Ray, A., Cot, M., Puzo, G., Gilleron, M. & Nigou, J. Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. Biochimie 95, 33-42 (2013).
11. Rockel, C. & Hartung, T. Systematic review of membrane components of gram-positive bacteria responsible as pyrogens for inducing human monocyte/macrophage cytokine release. Front Pharmacol. 3, 56 (2012).
12. Hashimoto, M. et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol 177, 3162-3169 (2006).
13. Zahringer, U., Lindner, B., Inamura, S., Heine, H. & Alexander, C. TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213, 205-224 (2008).
14. Stoll, H., Dengjel, J., Nerz, C. & Gotz, F. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect Immun 73, 2411-2423 (2005).
15. Gisch, N. et al. Structural reevaluation of Streptococcus pneumoniae lipoteichoic acid and new insights into its immunostimulatory potency. J Biol Chem 288, 15654-15667 (2013).
16. Pedersen, C. M. et al. Total synthesis of lipoteichoic acid of Streptococcus pneumoniae. Angewandte Chemie 49, 2585-2590 (2010).
17. Schmidt, R. R., Pedersen, C. M., Qiao, Y. & Zahringer, U. Chemical synthesis of bacterial lipoteichoic acids: an insight on its biological significance. Org Biomol Chem 9, 2040-2052 (2011).
18. Inamura, S. et al. Synthesis of peptidoglycan fragments and evaluation of their biological activity. Org Biomol Chem 4, 232-242 (2006).
19. Jin, M. S. et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071-1082 (2007).
20. Kang, J. Y. et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31, 873-884 (2009).
21. Farhat, K. et al. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol 83, 692-700 (2008).
22. Martinez de Tejada, G. et al. Bacterial cell wall compounds as promising targets of antimicrobial agents, I. Antimicrobial peptides and lipopolyamines. Curr Drug Targets 13, 1121-1130 (2012).
23. Schuerholz, T. et al. Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects. Curr Drug Targets 13, 1131-1137 (2012).
24. Heinbockel, L. et al. Broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors. Antimicr. Agents Chemother 57, 1480-1487 (2013).
25. Gutsmann, T. et al., New antiseptic peptides to protect from endotoxin-mediated shock. Antimicrob Agents Chemother 54, 3817-3824 (2010).
26. Kaconis, Y. et al. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 100, 2652-2661 (2011).
27. Schurholz, T. et al. Neue Sepsistherapie am Horizont: Antiinflammatorische Peptide. New sepsis therapies on the horizon: Antiinflammatory peptides DIVI 4, 144-152 (2013).
28. Schroder, N. W. et al. lipopolysaccharide Binding Protein Binds to Triacylated and Diacylated Lipopeptides and Mediates Innate Immune Responses. J Immunol 173, 2683-2691 (2004).
29. Peri, F. & Calabrese, V. Toll-like Receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. J Med Chem 57, 3612-3622 (2014).
30. van Bergenhenegouwen, J. et al. TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J Leukoc Biol 5, 885-902 (2013).
31. Ranoa, D. R., Kelley, S. L. & Tapping, R. I. Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem 288, 9729-9741 (2013).
32. Jain, S., Coats, S. R., Chang, A. M. & Darveau, R. P. A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by Porphyromonas gingivalis. Infect Immun 81, 1277-1286 (2013).
33. Schromm, A. B. et al. Physicochemical and biological analysis of synthetic bacterial lipopeptides: Validity of the concept of 'endotoxic conformation'. J Biol Chem 282, 11030-11037 (2007).
34. Schromm, A. B. et al. Influence of serum on the immune recognition of a synthetic lipopeptide mimetic of the 19-kDa lipoprotein from Mycobacterium tuberculosis. Inn Immun 16, 213-225 (2010).
35. Neilsen, P. O., Zimmerman, G. A. & McIntyre, T. M. Escherichia coli Braun lipoprotein induces a lipopolysaccharide-like endotoxic response from primary human endothelial cells. J Immunol 167, 5231-5239 (2001).
36. John, C. M., Liu, M. & Jarvis, G. A. Profiles of structural heterogeneity in native lipooligosaccharides of Neisseria and cytokine induction. J Lipid Res 50, 424-438 (2009).
37. Kenedy, M. R. et al. Structural modeling and physicochemical characterization provide evidence that P66 forms a.-Barrel in the Borrelia burgdorferi outer membrane. J Bacteriol 196, 859-872 (2014).
38. Reinhart, K., Bauer, M., Riedemann, N. C. & Hartog, C. S. New approaches to sepsis: Molecular diagnostics and biomarkers. Clin Microbiol Rev 25, 609-634 (2012).
39. Hubschle, T. et al. Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and-6 agonists MALP-2 and FSL-1. Am J Physiol Regul Integr Comp Physiol 290, R180-R187 (2006).
40. Greis A. et al. Characterization of the febrile response induced by fibroblast-stimulating lipopeptide-1 in guinea pigs. Am J Physiol Regul Integr Comp Physiol 293, R152-R161 (2007).
41. Schromm, A. B. et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 267, 2008-2013 (2000).
42. Andra, J. et al. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins. Thermodynamical, biophysical, and microbiological analysis. Biochem J 406, 297-307 (2007).
43. Garidel, P. & Brandenburg, K. Current understanding of Polymyxin B applications in bacteraemia/sepsis therapy prevention: Clinical, pharmaceutical, structural and mechanistic aspects, Antiinfect Agents Medic Chem 8, 367-385 (2009).
44. Opal, S. M. The clinical relevance of endotoxin in human sepsis: a critical analysis. J Endotoxin Res 8, 473-476 (2002).
45. Galanos, C., Luderitz, O. & Westphal, O. A new method for the extraction of R lipopolysaccharides. Eur J Biochem 9, 245-249 (1969).
46. Muller, P. et al. The Staphylococcus aureus lipoprotein SitC colocalizes with Toll-like receptor 2 (TLR2) in murine keratinocytes and elicits intracellular TLR2 accumulation. Infect Immun 78, 4243-4250 (2010).
47. de Jonge, B. L., Chang, Y. S., Gage, D. & Tomasz, A. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J Biol Chem 267, 11248-11254 (1992).
48. Galanos, C., Freudenberg, M. A. & Reutter, W. Galactosamine induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA. 76, 5939-5943 (1979).